![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Patient Enrollment Kicks Off in CoreValve Evolut R Study
Patient Enrollment Kicks Off in CoreValve Evolut R Study
![](https://www.fdanews.com/ext/resources/test/Device_Images3/Medtronic.gif?t=1433878552&width=430)
March 7, 2016
The first patients have been enrolled in a study to evaluate performance outcomes using the CoreValve EvolutR System in everyday clinical practice.
The study will enroll patients in at least 60 centers worldwide to evaluate the recapturable and repositionable transcatheter aortic valve implantation system. Centers in Europe, Australia, the Middle East, Africa, Latin America and Canada will participate in the study.
The CoreValve Evolut R is available in Europe and was approved for commercial use in the U.S. last year. — Elizabeth Hollis
Upcoming Events
-
21Oct